CleanCap technology is a proprietary, co-transcriptional 5’ capping solution that generates a natural Cap 1 structure. Proper mRNA capping is critical to the production of the most biologically active and least immunogenic mRNA. TriLink scientists developed CleanCap, the next generation of capping technology, as a solution to the low capping efficiencies (mCAP/ARCA) or high enzyme costs that are associated with traditional capping methods.
Leverage a legacy of trailblazing innovation in mRNA and 7+ years of GMP mRNA manufacturing with TriLink®. Bringing your mRNA vaccine or therapeutic through the clinic introduces new demands for process development, scalability, and quality. TriLink® leverages cGMP manufacturing processes to deliver mRNA drug substances at scale. Increase your probability of success by partnering with a global leader in mRNA development and manufacturing.
TriLink oligo scientists and production staff have over 150 years of collective experience with oligonucleotide chemistry and methods development. TriLink offers a wide selection of DNA, RNA, modified, and specialty oligonucleotides. Read more about how our decades of experience designing and synthesizing difficult constructs with unparalleled purity and performance make us a trusted partner for your application goals.
